# AR-V7 splice variant

Source: https://onco.cc/biomarkers/ar-v7-splice-variant/  
OnCo record `ar-v7-splice-variant` (Biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AR-V7 is a shortened androgen receptor that lacks the part hormone drugs bind, so it stays active without testosterone. Found in circulating tumour cells, it predicts poor response to abiraterone and enzalutamide, but no label uses it yet.

## Summary

The AR-V7 transcript skips the ligand-binding domain and is detected by RT-PCR of circulating tumour cell RNA or by nuclear AR-V7 protein immunofluorescence in CTCs (the Oncotype DX AR-V7 Nucleus Detect assay, a laboratory-developed test). The prospective PROPHECY trial (NCT02269982) showed that AR-V7-positive men had shorter progression-free and overall survival on abiraterone or enzalutamide, while taxane response was preserved. No regulator has put AR-V7 in a label and no companion diagnostic exists; it is a guideline-discussed, not guideline-mandated, test.

## Fields

- Kind: Biomarker
- Last checked: 2026-09-23
- Also known as: AR-V7; AR-V7 positive; androgen receptor splice variant 7; AR-V7 CTC; nuclear AR-V7
- Tags: biomarker; prostate; no-approval

## Sources

- PROPHECY (NCT02269982): https://clinicaltrials.gov/study/NCT02269982

## Connected records

- biomarkers: [PSMA expression by PET (PSMA-positive)](https://onco.cc/biomarkers/psma-pet-expression/)
- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/)
- terms: [AR-V7 splice variant](https://onco.cc/terms/ar-v7/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/)

---
JSON: https://onco.cc/api/v1/entities/ar-v7-splice-variant.json